Paradigm Biopharmaceuticals Limited
OTC: PBIGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul John Rennie
- Headquarters
- Melbourne, Australia
- IPO year
- 2019
- Market cap
- $55.1M
- Website
- https://www.paradigmbiopharma.com
Loading PBIGF…
Loading profile data…Frequently asked questions about PBIGF
What does Paradigm Biopharmaceuticals Limited (PBIGF) do?
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditio...
Where does PBIGF trade?
Paradigm Biopharmaceuticals Limited (PBIGF) trades on the Other OTC.
What sector is PBIGF in?
Paradigm Biopharmaceuticals Limited (PBIGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Paradigm Biopharmaceuticals Limited?
Paul John Rennie is the chief executive officer of Paradigm Biopharmaceuticals Limited (PBIGF).
Where is Paradigm Biopharmaceuticals Limited headquartered?
Paradigm Biopharmaceuticals Limited is headquartered in Australia.
Does PBIGF pay a dividend?
Paradigm Biopharmaceuticals Limited (PBIGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PBIGF go public?
Paradigm Biopharmaceuticals Limited (PBIGF) completed its initial public offering in 2019.